The full craft of drug hunting: discovery through first-in-human - assembled into one integrated engine, with one senior team accountable for the answer.
Most engagements begin at one of four points, depending on where your program sits today.
Independent, senior diligence on your asset, program, or R&D organization. Is the science relevant? Is it IND-ready? Where is the risk, and how do we accelerate?
The IND-enabling and preclinical package, built with trusted methods and human-relevant tools, including NAMs/MPS — the fastest defensible path to the clinic.
Fractional leadership to architect and run the engine around your program.
Integrate new methods and models. Develop and implement novel approaches.
Start from the decision you need to reach, then design the plan that gets there fastest.
A full bench across every discipline, sized to your program, no fixed overhead.
An extension of your team, accountable for the answer, not the assay.
Every result lands in one place and drives the next milestone cycle.
SPECCRO is the ‘architect’of end-to-end drug development strategy, guiding sponsors through every step of the process as a seamless extension of your internal team.
The engine runs as a loop: discovery biology, chemistry, protein sciences, ADME, PK, toxicology, computational, translational and regulatory, wired so every result sharpens the next design cycle. We pair trusted methods with human-relevant tools (including NAMs), chosen on the merits.
Execution hubs in Oncology, Neurology/Ophthalmology, Cardiorenal and Rare Diseases: delivering disease-aligned strategy, assays, and analytics.
Sponsors achieve faster go/no-go clarity and lower preclinical costs through streamlined, predictive workflows.
Our proprietary data architecture harmonizes multi-source inputs, from organ-on-chip to omics, enabling real-time insights, cross-study learning, and Al-powered decision support.
of drugs fail due to poor preclinical translation — we’re here to change that.
years of individual drug development experience across the leadership team.
of human diseases have approved treatments. Our mission is to change that.
is the cost of the development of a new therapy. We want to move the needle on that.